Study of ASP7517 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors Expressing WT1 Antigen
Status:
Recruiting
Trial end date:
2027-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, tolerability, and clinical response of
ASP7517, and determine the Recommended Phase 2 Dose (RP2D) and/or the Maximum Tolerated Dose
(MTD) of ASP7517 when administered as a single agent and in combination with pembrolizumab.
This study will also evaluate other measures of anticancer activity of ASP7517 when
administered as a single agent and in combination with pembrolizumab based on central and
local assessment.